The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The discontinuation of belantamab mafodotin for R/R multiple myeloma from the US market
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, explains the reasons behind the discontinuation of belantamab mafodotin from the Unites States (US) market for relapsed/refractory (R/R) multiple myeloma. Prof. Mohty describes how results from a recent randomized study indicated the inferior response belantamab mafodotin elicited compared to pomalidomide-dexamethasone (pom-dex), which has led to the discontinuation of the agent. However, Prof. Mohty remains optimistic and believes that belantamab mafodotin is still a valuable agent for multiple myeloma. Prof. Mohty further mentions that investigations of belantamab mafodotin in combination with other drugs may prove the efficacy and utility of the agent. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
